EBS: Once upon a time .... and now ....EBS:
Once upon a time .... and now ....
Wait n see!
US STOCKS- WALL STREET DREAM- LET'S THE MARKET SPEAK!
LongCompare with Emergent BioSolutions Inc.
−3.44 USD
52.60 M USD
742.90 M USD
48.20 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Joseph C. Papa
Website
Headquarters
Gaithersburg
Founded
1998
IPO date
Nov 15, 2006
ISIN
US29089Q1058
CUSIP
29089Q105
FIGI
BBG000GW06J7
Identifiers
ISIN US29089Q1058
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Long
ebs: reaching opex lowsome kind of periodicity recently on OPEX day's, but it is supposed to be the last one...
Long
Emergent BioSolutions Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Emergent BioSolutions Stock Quote
- Double Formation
* (Consolidation Argument)) At 4.50 USD
* 15.00 USD | Area Of Value | Subdivision 1
- Triple Formation
* (Open Trade)) At 13.00 U
Long
EBS: up to 12 Options resistance at 12 changed to support ! High Volume of 12 Put's as new resistance. On high buy Volume 12 resistance could be puvlerized ... waiting on mpox vaccine and narcan earnings. could see a surprise again.
Long
EBS: going to 16-20WHO just approved ACCAM2000 for mpox ! Although I bought it because of Narcan, this is GOOOD news. Waiting on EEE.Virus news. If this works also out we will be heading above 100
Long
Emergent BioSolutions | Chart & Forecast SummaryKey Indicators on Trade Set Up in General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session - 60 Minutes Time Frame
# Emergent BioSolutions - Based in Gaithersburg, Maryland | USA
- Trend Line 1&2 | Exchange Of Context
- WXY | Wave X | Point Of Control
- Inverted Head & Shoul
OD's In America EBS has THE main stream Narcan that dominates the market. With increasing over doses though out America. Earnings could make this move like crazyyyyyyyy.
If it is not this earnings then it is next, this stock can pop 50-100% in one day. Its a scalp trade.
Long
Emergent Bio: Clear LONGDidn't change much yesterday's data... It remains the only solution out of the lethality rates of current opioid crisis !!! Target above 30 . For most of us this is a once in a lifetime Opprtunity
Long
EBS Base Breakout SetupHey everybody got my camera working for this trade idea. Here we have the ebs stock setting up for a breakout in an uptrend and we're hoping for a bullish continuation here. I describe my entry points my stop loss and my profit target one and the logic behind them and how to position your share coun
Education
EBS - June 24 Qullamaggie Breakout and Episodic PivotThis is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting
Qulla Breakout & EP (Discretionary & Systematic) 🚀
Swing Trend Strategy focused on Breakouts based on repeated momentum and Episodic Pivots based on unexpected news/fundamentals that is not properly priced in.
Long
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateAug 15, 2028
Coupon3.88% (Fixed)
See all EBS bonds
Frequently asked questions
The current price of EBS is 6.75 USD — it has decreased by −0.31% in the past 24 hours. Watch Emergent BioSolutions Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Emergent BioSolutions Inc. stocks are traded under the ticker EBS.
EBS stock has risen by 3.41% compared to the previous week, the month change is a 41.33% rise, over the last year Emergent BioSolutions Inc. has showed a −15.63% decrease.
We've gathered analysts' opinions on Emergent BioSolutions Inc. future price: according to them, EBS price has a max estimate of 12.00 USD and a min estimate of 10.00 USD. Watch EBS chart and read a more detailed Emergent BioSolutions Inc. stock forecast: see what analysts think of Emergent BioSolutions Inc. and suggest that you do with its stocks.
EBS stock is 6.89% volatile and has beta coefficient of 0.90. Track Emergent BioSolutions Inc. stock price on the chart and check out the list of the most volatile stocks — is Emergent BioSolutions Inc. there?
Today Emergent BioSolutions Inc. has the market capitalization of 326.10 M, it has increased by 4.19% over the last week.
Yes, you can track Emergent BioSolutions Inc. financials in yearly and quarterly reports right on TradingView.
Emergent BioSolutions Inc. is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
EBS earnings for the last quarter are 0.60 USD per share, whereas the estimation was −0.09 USD resulting in a 805.88% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Emergent BioSolutions Inc. earnings.
Emergent BioSolutions Inc. revenue for the last quarter amounts to 234.30 M USD, despite the estimated figure of 177.50 M USD. In the next quarter, revenue is expected to reach 123.22 M USD.
EBS net income for the last quarter is −180.20 M USD, while the quarter before that showed 6.80 M USD of net income which accounts for 0.00% change. Track more Emergent BioSolutions Inc. financial stats to get the full picture.
No, EBS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 17, 2026, the company has 900 employees. See our rating of the largest employees — is Emergent BioSolutions Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Emergent BioSolutions Inc. EBITDA is 232.80 M USD, and current EBITDA margin is 28.07%. See more stats in Emergent BioSolutions Inc. financial statements.
Like other stocks, EBS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Emergent BioSolutions Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Emergent BioSolutions Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Emergent BioSolutions Inc. stock shows the sell signal. See more of Emergent BioSolutions Inc. technicals for a more comprehensive analysis.